Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 242

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

The Therapeutic Potential of Psilocybin

Open access
Lowe, Henry, Toyang, Ngeh, Steele, Blair, Valentine, Henkel, Grant, Justin, Ali, Amza, Ngwa, Wilfred, Gordon, Lorenzo·2021·Molecules

Abstract

The psychedelic effects of some plants and fungi have been known and deliberately exploited by humans for thousands of years. Fungi, particularly mushrooms, are the principal source of naturally occurring psychedelics. The mushroom extract, psilocybin has historically been used as a psychedelic agent for religious and spiritual ceremonies, as well as a therapeutic option for neuropsychiatric conditions. Psychedelic use was largely associated with the “hippie” counterculture movement, which, in turn, resulted in a growing, and still lingering, negative stigmatization for psychedelics. As a result, in 1970, the U.S. government rescheduled psychedelics as Schedule 1 drugs, ultimately ending scientific research on psychedelics. This prohibition on psychedelic drug research significantly delayed advances in medical knowledge on the therapeutic uses of agents such as psilocybin. A 2004 pilot study from the University of California, Los Angeles, exploring the potential of psilocybin treatment in patients with advanced-stage cancer managed to reignite interest and significantly renewed efforts in psilocybin research, heralding a new age in exploration for psychedelic therapy. Since then, significant advances have been made in characterizing the chemical properties of psilocybin as well as its therapeutic uses. This review will explore the potential of psilocybin in the treatment of neuropsychiatry-related conditions, examining recent advances as well as current research. This is not a systematic review.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/molecules26102948

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 57 references

Research works printed but not linked: 152

  1. Dyck, 2005, Flashback: Psychiatric Experimentation with LSD in Historical Perspective, Can. J. Psychiatry, 50, 381, 10.1177/070674370505000703 · DOI
  2. Johnson, 2017, Potential Therapeutic Effects of Psilocybin, Neurotherapeutics, 14, 734, 10.1007/s13311-017-0542-y · DOI · Paper page
  3. Schindler, 2015, Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey, J. Psychoact. Drugs, 47, 372, 10.1080/02791072.2015.1107664 · DOI
  4. Halberstadt, 2011, Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens, Neuropharmacology, 61, 364, 10.1016/j.neuropharm.2011.01.017 · DOI · Paper page
  5. Canal, C.E. (2018). Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action, New Psychoactive Substances; Springer Science and Business Media LLC. · DOI
  6. Hoyer, 1994, International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin), Pharmacol. Rev., 46, 157
  7. Frazer, 1999, Serotonin, Basic Neurochem., 6, 335
  8. Hendricks, 2015, Psilocybin, psychological distress, and suicidality, J. Psychopharmacol., 29, 1041, 10.1177/0269881115598338 · DOI
  9. Elflein, J. (2021, March 23). Psychedelic therapy—Statistics & Facts. Available online: https://www.statista.com/topics/4277/psychedelic-therapy/. · DOI
  10. Zamaria, J.A. (2016). A Phenomenological Examination of Psilocybin and its Positive and Persisting Aftereffects. NeuroQuantology, 14. · DOI
  11. Morgan, 2017, Tripping up addiction: The use of psychedelic drugs in the treatment of problematic drug and alcohol use, Curr. Opin. Behav. Sci., 13, 71, 10.1016/j.cobeha.2016.10.009 · DOI
  12. Griffiths, 2014, Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction, Curr. Drug Abuse Rev., 7, 157
  13. Daniel, 2017, Clinical potential of psilocybin as a treatment for mental health conditions, Ment. Health Clin., 7, 24, 10.9740/mhc.2017.01.024 · DOI
  14. Kim, 2014, Drugs currently in Phase II clinical trials for cocaine addiction, Expert Opin. Investig. Drugs, 23, 1105, 10.1517/13543784.2014.915312 · DOI
  15. Johnson, 2017, An online survey of tobacco smoking cessation associated with naturalistic psychedelic use, J. Psychopharmacol., 31, 841, 10.1177/0269881116684335 · DOI
  16. Wilcox, 2014, Psilocybin and Obsessive Compulsive Disorder, J. Psychoact. Drugs, 46, 393, 10.1080/02791072.2014.963754 · DOI
  17. Spiegel, 2016, Psilocybin-assisted psychotherapy for dying cancer patients—aiding the final trip, J. Psychopharmacol., 30, 1215, 10.1177/0269881116675783 · DOI
  18. Shelton, 2016, Psilocybin and palliative end-of-life care, J. Psychopharmacol., 30, 1207, 10.1177/0269881116675764 · DOI
  19. Lyons, 2018, Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression, J. Psychopharmacol., 32, 811, 10.1177/0269881117748902 · DOI · Paper page
  20. Beck, S. (2020). Psilocybin-Assisted Psychotherapy: Treating Depression and Anxiety with Mushrooms. Physician Assist. Stud. Stud. Artic., 7. · DOI
  21. Reynolds, C.F. (2020). Psilocybin-Assisted Supportive Psychotherapy in the Treatment of Major Depression—Quo Vadis?. JAMA Psychiatry. · DOI
  22. Roseman, L., Nutt, D.J., and Carhart-Harris, R.L. (2018). Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. Front. Pharmacol., 8. · DOI · Paper page
  23. Sewell, 2006, Response of cluster headache to psilocybin and LSD, Neurology, 66, 1920, 10.1212/01.wnl.0000219761.05466.43 · DOI · Paper page
  24. Whelan, 2018, Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: A potential role?, Pain Manag., 8, 217, 10.2217/pmt-2017-0068 · DOI
  25. Nkadimeng, S.M., Nabatanzi, A., Steinmann, C.M.L., and Eloff, J.N. (2020). Phytochemical, Cytotoxicity, Antioxidant and Anti-Inflammatory Effects of Psilocybe Natalensis Magic Mushroom. Plants, 9. · DOI
  26. Castellanos, 2020, Chronic pain and psychedelics: A review and proposed mechanism of action, Reg. Anesth. Pain Med., 45, 486, 10.1136/rapm-2020-101273 · DOI
  27. Ramachandran, 2018, Relief from intractable phantom pain by combining psilocybin and mirror visual-feedback (MVF), Neurocase, 24, 105, 10.1080/13554794.2018.1468469 · DOI
  28. Hendricks, P.S. (2020). Psilocybin-assisted group therapy: A new hope for demoralization. EClinicalMedicine, 27. · DOI
  29. Meldrum, 1971, Effects of psilocybin, dimethyltryptamine, mescaline and various lysergic acid derivatives on the EEG and on photically induced epilepsy in the baboon (Papio papio), Electroencephalogr. Clin. Neurophysiol., 31, 563, 10.1016/0013-4694(71)90072-1 · DOI
  30. Nichols, 2020, Psilocybin: From ancient magic to modern medicine, J. Antibiot., 73, 679, 10.1038/s41429-020-0311-8 · DOI · Paper page
  31. Heffter, 1898, Ueber Pellote, Arch. Exp. Pathol. Pharmakol., 40, 385, 10.1007/BF01825267 · DOI
  32. Schultes, 1969, Hallucinogens of Plant Origin, Science, 163, 245, 10.1126/science.163.3864.245 · DOI · Paper page
  33. Mithoefer, 2016, Novel psychopharmacological therapies for psychiatric disorders: Psilocybin and MDMA, Lancet Psychiatry, 3, 481, 10.1016/S2215-0366(15)00576-3 · DOI · Paper page
  34. Brenan, 1980, Plants of the Gods: Origins of Hallucinogenic Use, Kew Bull., 35, 708, 10.2307/4110029 · DOI
  35. 2015, Hallucinogenic drugs in pre-Columbian Mesoamerican cultures, Neurologia (Barcelona, Spain), 30, 42
  36. Davies, 1964, Lysergic acid (LSD 25) and ritalin in the treatment of neurosis, J. Psychosom. Res., 8, 164, 10.1016/0022-3999(64)90081-9 · doi:10.1016/0022-3999(64)90081-9
  37. Johnson, 1969, LSD in the Treatment of Alcoholism, Am. J. Psychiatry, 126, 481, 10.1176/ajp.126.4.481 · DOI
  38. Ludwig, 1969, A Clinical Study of LSD Treatment in Alcoholism, Am. J. Psychiatry, 126, 59, 10.1176/ajp.126.1.59 · DOI
  39. Smart, 1964, The efficacy of LSD in the treatment of alcoholism, Q. J. Stud. Alcohol, 25, 333, 10.15288/qjsa.1964.25.333 · DOI
  40. Visotsky, 1971, LSD and alcoholism: A clinical study of treatment efficacy, J. Chronic Dis., 24, 597, 10.1016/0021-9681(71)90050-6 · DOI
  41. Jordy, 1971, Book Reviews—LSD and alcoholism; a clinical study of treatment efficacy, Q. J. Stud. Alcohol, 32, 589, 10.15288/qjsa.1971.32.589 · doi:10.15288/qjsa.1971.32.589
  42. Dahlberg, 1968, Lysergic Acid Diethylamide (LSD) in the Treatment of Alcoholism, Arch. Gen. Psychiatry, 19, 508, 10.1001/archpsyc.1968.01740100124021 · DOI
  43. Abuzzahab, 1971, A review of LSD treatment in alcoholism, Int. Pharm., 6, 223
  44. Dyck, 2015, LSD: A new treatment emerging from the past, CMAJ Can. Med Assoc. J. J. l’Association Med Can., 187, 1079, 10.1503/cmaj.141358 · DOI
  45. Rice, 1992, An evaluation of a maximum security therapeutic community for psychopaths and other mentally disordered offenders, Law Hum. Behav., 16, 399, 10.1007/BF02352266 · DOI · Paper page
  46. Harris, 1994, Psychopaths: Is a therapeutic community therapeutic?, Int. J. Ther. Supportive Organ., 15, 283
  47. Reidy, 2013, Reducing psychopathic violence: A review of the treatment literature, Aggress. Violent Behav., 18, 527, 10.1016/j.avb.2013.07.008 · DOI
  48. Bender, 1961, Treatment of autistic schizophrenic children with LSD-25 and UML-491, Recent Adv. Biol. Psychiatry, 4, 170
  49. Bender, 1966, D-lysergic acid in the treatment of the biological features of childhood schizophrenia, Dis. Nerv. Syst., 7, 43
  50. Freedman, 1962, Autistic schizophrenic children. An experiment in the use of d-lysergic acid diethylamide (LSD-25), Arch. Gen. Psychiatry, 6, 203, 10.1001/archpsyc.1962.01710210019003 · DOI
  51. Simmons, 1972, The variable effects of LSD-25 on the behavior of a heterogeneous group of childhood schizophrenics, Behav. Neuropsychiatry, 4, 10
  52. Moller, 1964, The treatment of childhood schizophrenia in a public school system, Psychol. Sch., 1, 297, 10.1002/1520-6807(196407)1:3<297::AID-PITS2310010316>3.0.CO;2-T · doi:10.1002/1520-6807(196407)1:3<297::aid-pits2310010316>3.0.co;2-t
  53. Ball, 1961, The Use of L.S.D. 25 (D-Lysergic Acid Diethylamide) in the Treatment of the Sexual Perversions, Can. Psychiatr. Assoc. J., 6, 231, 10.1177/070674376100600407 · DOI
  54. Simmons, 1966, Modification of autistic behavior with LSD-25, Am. J. Psychiatry, 122, 1201, 10.1176/ajp.122.11.1201 · DOI
  55. Sigafoos, 2007, Flashback to the 1960s: LSD in the treatment of autism, Dev. Neurorehabilit., 10, 75, 10.1080/13638490601106277 · DOI
  56. Honigfeld, 1964, Temporal effects of LSD-25 and epinephrine on verbal behavior, PsycEXTRA Dataset, 70, 303
  57. Timothy, 1965, A new behavior change program using psilocybin, Psychotherapy, 2, 61, 10.1037/h0088612 · DOI
  58. Keusch, 2017, Rehabilitation in patients with pulmonary arterial hypertension, Swiss Med. Week., 147, w14462
  59. Leary, 1969, The effects of consciousness-expanding drugs on prisoner rehabilitation, Psychedelic Rev., 10, 29
  60. Doblin, 1991, Pahnke’s "Good Friday experiment": A long-term follow-up and methodological critique, J. Transpers. Psychol., 23, 1
  61. Kargbo, 2020, Psilocybin Therapeutic Research: The Present and Future Paradigm, ACS Med. Chem. Lett., 11, 399, 10.1021/acsmedchemlett.0c00048 · DOI
  62. Hoch, 1952, Effects of mescaline and lysergic acid (d-LSD-25), Am. J. Psychiatry, 108, 579, 10.1176/ajp.108.8.579 · DOI
  63. Bahr, 2019, Intranasal Esketamine (SpravatoTM) for Use in Treatment-Resistant Depression In Conjunction With an Oral Antidepressant, P T Peer-Rev. J. Formul. Manag., 44, 340
  64. Stamets, P., and Weil, A. (1996). Psilocybin Mushrooms of the World: An Identification Guide, Ten Speed Press. [1st ed.].
  65. Griffiths, R.R., Hurwitz, E.S., Davis, A.K., Johnson, M.W., and Jesse, R. (2019). Survey of subjective “God encounter experiences”: Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. PLoS ONE, 14. · DOI · Paper page
  66. Barrett, F.S., Krimmel, S.R., Griffiths, R.R., Seminowicz, D.A., and Mathur, B.N. (2020). Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention. NeuroImage, 218. · DOI · Paper page
  67. Carbonaro, 2020, Subjective features of the psilocybin experience that may account for its self-administration by humans: A double-blind comparison of psilocybin and dextromethorphan, Psychopharmacology, 237, 2293, 10.1007/s00213-020-05533-9 · DOI
  68. Griffiths, 2008, Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later, J. Psychopharmacol., 22, 621, 10.1177/0269881108094300 · DOI · Paper page
  69. Doblin, 1998, Dr. Leary’s Concord Prison Experiment: A 34-Year Follow-up Study, J. Psychoact. Drugs, 30, 419, 10.1080/02791072.1998.10399715 · DOI
  70. Leary, 1963, Reactions to psilocybjn administered in a supportive environment, J. Nerv. Ment. Dis., 137, 561, 10.1097/00005053-196312000-00007 · DOI · Paper page
  71. Kelmendi, 2016, The role of psychedelics in palliative care reconsidered: A case for psilocybin, J. Psychopharmacol., 30, 1212, 10.1177/0269881116675781 · DOI
  72. Guss, J., Krause, R., and Sloshower, J. (2020). The Yale Manual for Psilocybin-Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame). PsyArXiv. · DOI
  73. Yale University (2021, March 25). Psilocybin for the Treatment of Cluster Headache, Available online: https://clinicaltrials.gov/ct2/show/NCT02981173. · DOI
  74. Petranker, R., Kim, J., and Anderson, T. (2020). Microdosing as a response to the meaning crisis. PsyArXiv. · DOI
  75. Petranker, R., Anderson, T., Maier, L.J., Barratt, M.J., A Ferris, J., and Winstock, A.R. (2020). Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention. J. Psychopharmacol. · DOI
  76. Hasler, 1997, Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man, Pharm. Acta Helv., 72, 175, 10.1016/S0031-6865(97)00014-9 · DOI · Paper page
  77. 2014, Psilocybin Summary of knowledge and new perspectives, Eur. Neuropsychopharmacol., 24, 342, 10.1016/j.euroneuro.2013.12.006 · DOI · Paper page
  78. Horita, 1963, Some biochemical studies on psilocybin and psilogin, J. Neuropsychiatr., 4, 270
  79. Fricke, 2020, Scalable Hybrid Synthetic/Biocatalytic Route to Psilocybin, Chem. A Eur. J., 26, 8281, 10.1002/chem.202000134 · DOI
  80. Nichols, 1999, Improvements to the Synthesis of Psilocybin and a Facile Method for Preparing the O-Acetyl Prodrug of Psilocin, Synthesis, 1999, 935, 10.1055/s-1999-3490 · DOI
  81. Ullrich, 2007, Enzymatic hydroxylation of aromatic compounds, Cell. Mol. Life Sci., 64, 271, 10.1007/s00018-007-6362-1 · DOI · Paper page
  82. Fricke, 2017, Enzymatic Synthesis of Psilocybin, Angew. Chem. Int. Ed., 56, 12352, 10.1002/anie.201705489 · DOI · Paper page
  83. Hoefgen, 2018, Facile assembly and fluorescence-based screening method for heterologous expression of biosynthetic pathways in fungi, Metab. Eng., 48, 44, 10.1016/j.ymben.2018.05.014 · DOI
  84. Adams, 2019, In vivo production of psilocybin in E. coli, Metab. Eng., 56, 111, 10.1016/j.ymben.2019.09.009 · DOI
  85. Milne, 2020, Metabolic engineering of Saccharomyces cerevisiae for the de novo production of psilocybin and related tryptamine derivatives, Metab. Eng., 60, 25, 10.1016/j.ymben.2019.12.007 · DOI
  86. Borodina, 2014, Advances in metabolic engineering of yeast Saccharomyces cerevisiae for production of chemicals, Biotechnol. J., 9, 609, 10.1002/biot.201300445 · DOI · Paper page
  87. Hassan, Z., Bosch, O.G., Singh, D., Narayanan, S., Kasinather, B.V., Seifritz, E., Kornhuber, J., Quednow, B.B., and Müller, C.P. (2017). Novel Psychoactive Substances—Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs. Front. Psychiatry, 8. · DOI
  88. Nava, 2019, Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines, Adv. Pharmacol. Sci., 2019, 1
  89. Mahapatra, 2017, Role of psilocybin in the treatment of depression, Ther. Adv. Psychopharmacol., 7, 54, 10.1177/2045125316676092 · DOI
  90. Holtzheimer, 2011, Stuck in a rut: Rethinking depression and its treatment, Trends Neurosci., 34, 1, 10.1016/j.tins.2010.10.004 · DOI · Paper page
  91. Grimm, 2018, Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination, Eur. Neuropsychopharmacol., 28, 691, 10.1016/j.euroneuro.2018.03.016 · DOI
  92. Tagliazucchi, 2014, Enhanced repertoire of brain dynamical states during the psychedelic experience, Hum. Brain Mapp., 35, 5442, 10.1002/hbm.22562 · DOI · Paper page
  93. Lord, 2019, Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin, NeuroImage, 199, 127, 10.1016/j.neuroimage.2019.05.060 · DOI · Paper page
  94. Bortolozzi, 2010, Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT1A receptors but not 5-HT2A receptors, Int. J. Neuropsychopharmacol., 13, 1299, 10.1017/S146114571000009X · DOI
  95. Schellekens, 2016, Psilocybin for treating substance use disorders?, Expert Rev. Neurother., 17, 203
  96. Nagaeva, E., Zubarev, I., Gonzales, C.B., Forss, M., Nikouei, K., De Miguel, E., Elsilä, L., Linden, A.-M., Hjerling-Leffler, J., and Augustine, G.J. (2020). Heterogeneous somatostatin-expressing neuron population in mouse ventral tegmental area. eLife, 9. · DOI
  97. Dailly, 2004, Dopamine, depression and antidepressants, Fundam. Clin. Pharmacol., 18, 601, 10.1111/j.1472-8206.2004.00287.x · DOI · Paper page
  98. Maust, 2016, Agitation in Alzheimer Disease as a Qualifying Condition for Medical Marijuana in the United States, Am. J. Geriatr. Psychiatry, 24, 1000, 10.1016/j.jagp.2016.03.006 · DOI
  99. Grandjean, J., Buehlmann, D., Buerge, M., Sigrist, H., Seifritz, E., Vollenweider, F.X., Pryce, C.R., and Rudin, M. (2021). Psilocybin exerts distinct effects on resting state networks associated with serotonin and dopamine in mice. NeuroImage, 225. · DOI
  100. Coull, 2010, Neuroanatomical and Neurochemical Substrates of Timing, Neuropsychopharmacology, 36, 3, 10.1038/npp.2010.113 · DOI · Paper page
  101. Hindley, 2020, Psychiatric symptoms abused by cannabis constituents: A systematic review and meta-analysis, Lancet Psychiatry, 7, 344, 10.1016/S2215-0366(20)30074-2 · DOI · Paper page
  102. Geyer, 2015, Lysergic Acid Diethylamide and Psilocybin Revisited, Biol. Psychiatry, 78, 516, 10.1016/j.biopsych.2015.08.003 · DOI
  103. Mertens, 2020, Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression, J. Psychopharmacol., 34, 167, 10.1177/0269881119895520 · DOI · Paper page
  104. Stroud, 2018, Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression, Psychopharmacol., 235, 459, 10.1007/s00213-017-4754-y · DOI
  105. Creese, 1975, The dopamine receptor: Differential binding of d-LSD and related agents to agonist and antagonist states, Life Sci., 17, 1715, 10.1016/0024-3205(75)90118-6 · DOI · Paper page
  106. Roseman, L., Leech, R., Feilding, A., Nutt, D.J., and Carhart-Harris, R.L. (2014). The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers. Front. Hum. Neurosci., 8. · DOI · Paper page
  107. Kong, 2013, Functional connectivity between the amygdala and prefrontal cortex in medication-naive individuals with major depressive disorder, J. Psychiatry Neurosci., 38, 417, 10.1503/jpn.120117 · DOI · Paper page
  108. IIsbell, 1959, Comparison of the reactions induced by psilocybin and LSD-25 in man, Psychopharmacol., 1, 29, 10.1007/BF00408109 · DOI
  109. Hollister, 1961, Clinical, biochemical and psychologic effects of psilocybin, Arch. Int. Pharmacodyn. Ther., 130, 42
  110. James, E., Robertshaw, T.L., Hoskins, M., and Sessa, B. (2020). Psilocybin occasioned mystical-type experiences. Hum. Psychopharmacol. Clin. Exp., 35. · DOI
  111. Erritzoe, 2018, Effects of psilocybin therapy on personality structure, Acta Psychiatr. Scand., 138, 368, 10.1111/acps.12904 · DOI · Paper page
  112. Forstmann, 2017, Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness, J. Psychopharmacol., 31, 975, 10.1177/0269881117714049 · DOI
  113. Hendricks, 2018, The relationships of classic psychedelic use with criminal behavior in the United States adult population, J. Psychopharmacol., 32, 37, 10.1177/0269881117735685 · DOI
  114. Walsh, 2016, Hallucinogen use and intimate partner violence: Prospective evidence consistent with protective effects among men with histories of problematic substance use, J. Psychopharmacol., 30, 601, 10.1177/0269881116642538 · DOI
  115. Hendricks, 2015, Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population, J. Psychopharmacol., 29, 280, 10.1177/0269881114565653 · DOI · Paper page
  116. MacLean, 2011, Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness, J. Psychopharmacol., 25, 1453, 10.1177/0269881111420188 · DOI · Paper page
  117. Nour, 2017, Psychedelics, Personality and Political Perspectives, J. Psychoact. Drugs, 49, 182, 10.1080/02791072.2017.1312643 · DOI · Paper page
  118. Miller, 2004, The phenomenon of quantum change, J. Clin. Psychol., 60, 453, 10.1002/jclp.20000 · DOI · Paper page
  119. Sherwood, 2020, Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin, Baeocystin, Norpsilocin, and Aeruginascin, J. Nat. Prod., 83, 461, 10.1021/acs.jnatprod.9b01061 · DOI
  120. Blei, 2020, Simultaneous Production of Psilocybin and a Cocktail of β-Carboline Monoamine Oxidase Inhibitors in “Magic” Mushrooms, Chemistry, 26, 729, 10.1002/chem.201904363 · DOI
  121. Gartz, 1989, Biotransformation of tryptamine derivatives in mycelial cultures ofPsilocybe, J. Basic Microbiol., 29, 347, 10.1002/jobm.3620290608 · DOI
  122. Matsushima, 2009, Effects of Psilocybe argentipes on marble-burying behavior in mice, Biosci. Biotechnol. Biochem., 73, 1866, 10.1271/bbb.90095 · DOI
  123. Gartz, 1987, Variation of the amount of Alkaloids in Fruit Bodies of Inocybe aeruginascens, Planta Med., 53, 539, 10.1055/s-2006-962805 · doi:10.1055/s-2006-962805
  124. Jensen, 2006, Aeruginascin, a Trimethylammonium Analogue of Psilocybin from the Hallucinogenic Mushroom Inocybe aeruginascens, Planta Med., 72, 665, 10.1055/s-2006-931576 · DOI
  125. Chadeayne, 2020, Active Metabolite of Aeruginascin (4-Hydroxy-N,N,N-trimethyltryptamine): Synthesis, Structure, and Serotonergic Binding Affinity, ACS Omega, 5, 16940, 10.1021/acsomega.0c02208 · DOI
  126. Gartz, 1989, Analysis of Aeruginascin in Fruit Bodies of the Mushroom Inocybe aeruginascens, Int. J. Crude Drug Res., 27, 141, 10.3109/13880208909053954 · DOI
  127. Fricke, 2019, Production Options for Psilocybin: Making of the Magic, Chem. A Eur. J., 25, 897, 10.1002/chem.201802758 · DOI
  128. 1975, Factors affecting drug action, Aust. Nurses J., 4, 21
  129. Ona, 2018, Inside bad trips: Exploring extra-pharmacological factors, J. Psychedelic Stud., 2, 53, 10.1556/2054.2018.001 · DOI
  130. Subra, 2009, A message in a bottle: Extrapharmacological effects of alcohol on aggression, J. Exp. Soc. Psychol., 45, 137, 10.1016/j.jesp.2008.07.018 · DOI
  131. Ahmed, 2020, Non-pharmacological factors that determine drug use and addiction, Neurosci. Biobehav. Rev., 110, 3, 10.1016/j.neubiorev.2018.08.015 · DOI
  132. Olson, 2020, Tripping on nothing: Placebo psychedelics and contextual factors, Psychopharmacology, 237, 1371, 10.1007/s00213-020-05464-5 · DOI
  133. Peden, 1982, The Problem of Psilocybin Mushroom Abuse, Hum. Toxicol., 1, 417, 10.1177/096032718200100408 · DOI
  134. Hyde, 1978, Abuse of Indigenous Psilocybin Mushrooms: A New Fashion and Some Psychiatric Complications, Br. J. Psychiatry, 132, 602, 10.1192/bjp.132.6.602 · DOI
  135. Vollenweider, 1998, Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action, NeuroReport, 9, 3897, 10.1097/00001756-199812010-00024 · DOI · Paper page
  136. Opperhuizen, 2011, Harm potential of magic mushroom use: A review, Regul. Toxicol. Pharmacol., 59, 423, 10.1016/j.yrtph.2011.01.006 · DOI · Paper page
  137. Jo, 2014, Toxicological Profiles of Poisonous, Edible, and Medicinal Mushrooms, Mycobiology, 42, 215, 10.5941/MYCO.2014.42.3.215 · doi:10.5941/myco.2014.42.3.215
  138. Bouso, 2018, Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: A systematic review of systematic reviews, Expert Rev. Clin. Pharmacol., 11, 889, 10.1080/17512433.2018.1511424 · DOI · Paper page
  139. Gable, 1993, Toward a Comparative Overview of Dependence Potential and Acute Toxicity of Psychoactive Substances Used Nonmedically, Am. J. Drug Alcohol Abus., 19, 263, 10.3109/00952999309001618 · DOI
  140. Gable, 2004, Comparison of acute lethal toxicity of commonly abused psychoactive substances, Addiction, 99, 686, 10.1111/j.1360-0443.2004.00744.x · DOI · Paper page
  141. Fantegrossi, 2004, Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys, Behav. Pharmacol., 15, 149, 10.1097/00008877-200403000-00007 · DOI · Paper page
  142. Lim, 2012, A fatal case of ‘magic mushroom’ ingestion in a heart transplant recipient, Intern. Med. J., 42, 1268, 10.1111/j.1445-5994.2012.02955.x · DOI
  143. 2013, Suizid unter Psilocin-Einfluss [Suicide under the influence of “magic mushrooms”], Arch. Kriminol., 231, 193
  144. Byock, 2018, Taking Psychedelics Seriously, J. Palliat. Med., 21, 417, 10.1089/jpm.2017.0684 · DOI · Paper page
  145. Appel, 1968, Tolerance and cross-tolerance among psychotomimetic drugs, Psychopharmacol., 13, 267, 10.1007/BF00401404 · DOI
  146. Passie, 2008, The Pharmacology of Lysergic Acid Diethylamide: A Review, CNS Neurosci. Ther., 14, 295, 10.1111/j.1755-5949.2008.00059.x · DOI · Paper page
  147. Strassman, R. (2008). Inner Paths to Outer Space: Journeys to Alien Worlds through Psychedelics and Other Spiritual Technologies, Paperback Edition; Park Street Press.
  148. Freye, E. (2009). The Mushroom Psilocybin with Psychedelic Properties. Pharmacology and Abuse of Cocaine, Amphetamines, Ecstasy and Related Designer Drugs, Springer Science and Business Media LLC. · DOI
  149. Gable, 2006, The Toxicity of Recreational Drugs, Am. Sci., 94, 207, 10.1511/2006.59.206 · doi:10.1511/2006.59.206
  150. Hasler, 2002, Renal excretion profiles of psilocin following oral administration of psilocybin: A controlled study in man, J. Pharm. Biomed. Anal., 30, 331, 10.1016/S0731-7085(02)00278-9 · DOI
  151. Kamata, 2006, Direct detection of serum psilocin glucuronide by LC/MS and LC/MS/MS: Time-courses of total and free (unconjugated) psilocin concentrations in serum specimens of a “magic mushroom” user, Forensic Toxicol., 24, 36, 10.1007/s11419-006-0006-2 · DOI
  152. Shoda, 2011, Enzyme-assisted synthesis of the glucuronide conjugate of psilocin, an hallucinogenic component of magic mushrooms, Drug Test. Anal., 3, 594, 10.1002/dta.244 · DOI

Cited by

See all 242

Metadata

Authors
Lowe, H., Toyang, N., Steele, B., Valentine, H., Grant, J., Ali, A., Ngwa, W., & Gordon, L.
Venue
Molecules
Publisher
MDPI AG
Published
2021-05-15
Volume
26
Issue
10
Pages
2948
ISSN
1420-3049 (ISSN-L)
OpenAlex
W3161556967
Cited by
242
References
57
FWCI
22.48
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Therapeutic Potential of Psilocybin. https://app.cochat.ai/papers/10.3390/molecules26102948
The paper
Lowe, H., Toyang, N., Steele, B., Valentine, H., Grant, J., Ali, A., Ngwa, W., & Gordon, L. (2021). The Therapeutic Potential of Psilocybin. Molecules. https://doi.org/10.3390/molecules26102948

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.